Crossmark

ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study

Crossref DOI link: https://doi.org/10.1038/s41388-022-02582-6

Published Online: 2022-12-23

Published Print: 2023-02-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lemech, Charlotte Rose

Kichenadasse, Ganessan

Marschner, Jens-Peter http://orcid.org/0000-0002-3458-9605
Alevizopoulos, Konstantinos

Otterlei, Marit http://orcid.org/0000-0002-5232-1186
Millward, Michael
License Information

Text and Data Mining valid from 2022-12-23

Version of Record valid from 2022-12-23
More Information

Article History

Received: 13 October 2022

Revised: 8 December 2022

Accepted: 13 December 2022

First Online: 23 December 2022

Competing interests

: CL and GK have nothing to declare. J-PM and KA are employees of Therapim Pty Ltd and its parent company, APIM Therapeutics AS. MO is an employee of Therapim Pty Ltd and its parent company, APIM Therapeutics AS; Founder of APIM Therapeutics AS; and Shareholder of APIM Therapeutics AS. MM is/was consultant or has/had an advisory role for the following companies: Roche, Bristol-Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Novartis, Pfizer/EMD Serono, Takeda, Guardant Health, Limbic, Beigene, Amgen, Merck, IQVIA, Eli Lilly. In addition, his institution received research funding from the following companies: Bristol-Myers Squibb, Novartis, Roche, AstraZeneca, Takeda, GlaxoSmithKline, BeiGene, Lilly, Apollomics, Albion, AkesoBio, AbbVie, C-Stone Pharmaceuticals, Therapim, Five Prime Therapeutics, Dizal, Maxinovel, Atridia, INXMED, Alpine Immune Sciences, Turning Point Therapeutics, IMPACT Therapeutics, Kinnate Biopharma, Cullinan MICA Corp.

Document is current

Any future updates will be listed below